181 related articles for article (PubMed ID: 35377986)
1. The Potential Oncostatic Effects of Melatonin against Prostate Cancer.
Samanta S
Crit Rev Oncog; 2021; 26(3):53-67. PubMed ID: 35377986
[TBL] [Abstract][Full Text] [Related]
2. Melatonin: A Potential Antineoplastic Agent in Breast Cancer.
Samanta S
J Environ Pathol Toxicol Oncol; 2022; 41(4):55-84. PubMed ID: 36374962
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic actions of melatonin in cancer: possible mechanisms.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Integr Cancer Ther; 2008 Sep; 7(3):189-203. PubMed ID: 18815150
[TBL] [Abstract][Full Text] [Related]
4. Melatonin: an endogenous miraculous indolamine, fights against cancer progression.
Samanta S
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1893-1922. PubMed ID: 32583237
[TBL] [Abstract][Full Text] [Related]
5. Melatonin and its ubiquitous anticancer effects.
Bhattacharya S; Patel KK; Dehari D; Agrawal AK; Singh S
Mol Cell Biochem; 2019 Dec; 462(1-2):133-155. PubMed ID: 31451998
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression.
Xi SC; Siu SW; Fong SW; Shiu SY
Prostate; 2001 Jan; 46(1):52-61. PubMed ID: 11170132
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative action of melatonin on human prostate cancer LNCaP cells.
Moretti RM; Marelli MM; Maggi R; Dondi D; Motta M; Limonta P
Oncol Rep; 2000; 7(2):347-51. PubMed ID: 10671684
[TBL] [Abstract][Full Text] [Related]
8. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy.
Targhazeh N; Reiter RJ; Rahimi M; Qujeq D; Yousefi T; Shahavi MH; Mir SM
Biochimie; 2022 Nov; 202():34-48. PubMed ID: 35752221
[TBL] [Abstract][Full Text] [Related]
9. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype.
Shiu SY; Law IC; Lau KW; Tam PC; Yip AW; Ng WT
J Pineal Res; 2003 Oct; 35(3):177-82. PubMed ID: 12932201
[TBL] [Abstract][Full Text] [Related]
10. [Melatonin: what for?].
Touitou Y
Bull Acad Natl Med; 2005 May; 189(5):879-89; discussion 889-91. PubMed ID: 16433460
[TBL] [Abstract][Full Text] [Related]
11. Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α
Tai HC; Wang SW; Swain S; Lin LW; Tsai HC; Liu SC; Wu HC; Guo JH; Liu CL; Lai YW; Lin TH; Yang SF; Tang CH
J Pineal Res; 2022 Apr; 72(3):e12793. PubMed ID: 35174530
[TBL] [Abstract][Full Text] [Related]
12. Melatonin Analogue Antiproliferative and Cytotoxic Effects on Human Prostate Cancer Cells.
Calastretti A; Gatti G; Lucini V; Dugnani S; Canti G; Scaglione F; Bevilacqua A
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783631
[TBL] [Abstract][Full Text] [Related]
13. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells.
Marelli MM; Limonta P; Maggi R; Motta M; Moretti RM
Prostate; 2000 Nov; 45(3):238-44. PubMed ID: 11074526
[TBL] [Abstract][Full Text] [Related]
14. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy.
Blask DE; Sauer LA; Dauchy RT
Curr Top Med Chem; 2002 Feb; 2(2):113-32. PubMed ID: 11899096
[TBL] [Abstract][Full Text] [Related]
15. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT).
Konturek SJ; Konturek PC; Brzozowska I; Pawlik M; Sliwowski Z; Cześnikiewicz-Guzik M; Kwiecień S; Brzozowski T; Bubenik GA; Pawlik WW
J Physiol Pharmacol; 2007 Sep; 58(3):381-405. PubMed ID: 17928638
[TBL] [Abstract][Full Text] [Related]
16. Melatonin: Physiological effects in humans.
Claustrat B; Leston J
Neurochirurgie; 2015; 61(2-3):77-84. PubMed ID: 25908646
[TBL] [Abstract][Full Text] [Related]
17. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
18. [MT1 melatonin receptors and their role in the oncostatic action of melatonin].
Danielczyk K; Dziegiel P
Postepy Hig Med Dosw (Online); 2009 Sep; 63():425-34. PubMed ID: 19837985
[TBL] [Abstract][Full Text] [Related]
19. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.
Mayo JC; Hevia D; Quiros-Gonzalez I; Rodriguez-Garcia A; Gonzalez-Menendez P; Cepas V; Gonzalez-Pola I; Sainz RM
J Pineal Res; 2017 Jan; 62(1):. PubMed ID: 27736013
[TBL] [Abstract][Full Text] [Related]
20. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors.
Pfeffer M; Rauch A; Korf HW; von Gall C
Chronobiol Int; 2012 May; 29(4):415-29. PubMed ID: 22489607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
